Molnupiravir (Lagevrio) is an oral antiviral for treating patients with COVID-19 in the community.
Access criteria are the same as for nirmatrelvir/ritonavir (Paxlovid). Molnupiravir should only be used where nirmatrelvir/ritonavir is clinically inappropriate, as trial data suggest molnupiravir is much less effective. Read our article for details.